Leading pharmaceutical manufacturer Renata Pharmaceuticals has recently achieved the historic milestone of producing 100 bioequivalent drugs. This significant success has positioned the company firmly in the global pharmaceutical market. Currently, Renata exports its manufactured medicines to a total of 60 countries across Europe, America, Africa, and Asia, a feat rooted in its continuous efforts in bioequivalence research and product development. This achievement has made the presence of Bangladesh's pharmaceutical industry more visible and stronger in the international market.
The story behind Renata's success is long and far-reaching. According to Syed S. Kaiser Kabir, the company's Chief Executive Officer and Managing Director, Renata is essentially the successor to the renowned Pfizer Corporation. In 1993, Pfizer Laboratories (Bangladesh) Limited transformed and emerged as Renata. From its inception, Renata has placed special emphasis on developing new and high-quality medicines. Alongside supplying affordable medicines for the people of the country, exporting medicines to the international market was also one of their primary goals.
Around 2015, while Renata was exploring avenues for exporting medicines abroad, a European pharmaceutical businessman asked Syed S. Kaiser Kabir how many bioequivalent products Renata had. In response, he stated that they had no bioequivalent products at that time. The gentleman then remarked that, in such a situation, Renata effectively had no products. This incident inspired Renata to understand the importance of developing bioequivalent drugs and to pursue this path. Since then, the company has focused on the development and research of bioequivalent drugs, achieving consistent success.
Bioequivalence is one of the primary scientific benchmarks for ensuring quality control and efficacy in the pharmaceutical sector. For any Bangladeshi company, it is an extremely crucial factor for exporting medicines. Only by meeting this benchmark is it possible to export medicines to international markets, especially to countries like the United States and Europe, where laws concerning medicines and pharmaceutical products are extremely stringent and specific. Renata has successfully met this challenging standard by developing 100 bioequivalent drugs, one after another, which is truly an achievement worth celebrating.
To the general public, the concept of bioequivalence might seem somewhat complex. Simply put, when two drugs from different manufacturers contain the same generic ingredients and the same strength, if, after administration to the human body, the rate and total amount of drug absorption into the blood plasma are equivalent, then the two drugs are considered 'bioequivalent' to each other. We generally do not discover new drugs; rather, we produce generic versions of patented drugs discovered by others. Bioequivalence is the scientific method to ensure that the efficacy of these generic drugs is equivalent to that of the original drug.
When a patent of an original company expires and other companies produce the same generic drug, it is not enough for the chemical composition to be correct. Bioequivalence testing is essential to ensure that the generic drug works in the patient's body at the same rate and extent as the original drug. This test ensures that even with a lower-priced generic drug, the quality of treatment will not be compromised in any way. Submitting a bioequivalence study report is mandatory for exporting medicines to developed markets like the United States or the European Union, which further enhances the significance of Renata's achievement.
Bioequivalence testing is typically a type of clinical trial conducted on humans or healthy volunteers. In the first phase of this process, a group of healthy volunteers (usually aged 18-45, with no complex diseases) is selected. Then, the original innovator's drug is administered to the volunteers at a specific dose, and the level of drug absorption into their blood plasma is monitored. After a certain period, once the previous drug has been completely eliminated from the body, the generic drug under investigation is administered to them at the same dose, and the rate and total amount of absorption into the blood plasma are monitored in the same manner. In both cases, the obtained results are analyzed to determine the bioequivalence of the two drugs. By following this rigorous scientific method, Renata has achieved its milestone of 100 bioequivalent drugs, establishing itself as a trusted and reliable name in the international market.
